A randomized controlled phase II trial of riluzole in early multiple sclerosis

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

Molecular mechanisms linking neuroinflammation and neurodegeneration in MS

(2014) Erik Ellwardt et al.   EXPERIMENTAL NEUROLOGY

Neuroprotection in Multiple Sclerosis: A Therapeutic Approach

(2013) Amir-Hadi Maghzi et al.   CNS DRUGS

A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis

(2012) Kurt-Wolfram Sühs et al.   ANNALS OF NEUROLOGY

EDSS variability before randomization may limit treatment discovery in primary progressive MS

(2012) Jiameng Zhang et al.   Multiple Sclerosis Journal

Color vision is strongly associated with retinal thinning in multiple sclerosis

(2012) Pablo Villoslada et al.   Multiple Sclerosis Journal

Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study

(2012) E. Waubant et al.   NEUROLOGY

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

(2010) Raju Kapoor et al.   LANCET NEUROLOGY

Riluzole in cerebellar ataxia: A randomized, double-blind, placebo-controlled pilot trial

(2010) G. Ristori et al.   NEUROLOGY

Rate of Brain Atrophy in Benign vs Early Multiple Sclerosis

(2009) Susan A. Gauthier et al.   ARCHIVES OF NEUROLOGY

Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures

(2009) E. M. Mowry et al.   NEUROLOGY

Gray matter atrophy in multiple sclerosis: A longitudinal study

(2008) Elizabeth Fisher et al.   ANNALS OF NEUROLOGY

Gray matter atrophy is related to long-term disability in multiple sclerosis

(2008) Leonora K. Fisniku et al.   ANNALS OF NEUROLOGY